Bayer to make clinical trial data more accessible to researchers

German drug major Bayer (BAYN: DE) has joined a host of other pharma companies in announcing that it will start sharing data from its clinical studies online.

Qualified researchers can request anonymized patient-level data from Bayer HealthCare sponsored clinical studies listed on the website. By joining the portal Bayer HealthCare is supporting efforts of the European Medicines Agency (EMA) to increase the transparency of data from clinical studies as well as complying with the principles of pharmaceutical trade associations EFPIA and PhRMA. German drug major Boehringer Ingelheim said on Monday that it is also engaged in a program to make clinical study data and related documents more widely accessible

Joerg Moeller, member of the Bayer HealthCare Executive Committee and Head of Global Development, said: “Our commitment to clinical trial transparency reflects our will to foster scientific research and hence public health. Joining the electronic platform and providing access to anonymized patient-level data, protocols and clinical study reports is a further step towards increased transparency while maintaining patient privacy.”